[go: up one dir, main page]

NO981864L - Upl ° sningsmetoder - Google Patents

Upl ° sningsmetoder

Info

Publication number
NO981864L
NO981864L NO981864A NO981864A NO981864L NO 981864 L NO981864 L NO 981864L NO 981864 A NO981864 A NO 981864A NO 981864 A NO981864 A NO 981864A NO 981864 L NO981864 L NO 981864L
Authority
NO
Norway
Prior art keywords
sningsmetoder
upl
proteins
biologically active
active compounds
Prior art date
Application number
NO981864A
Other languages
Norwegian (no)
Other versions
NO981864D0 (en
Inventor
Roger Randal Charles New
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Publication of NO981864D0 publication Critical patent/NO981864D0/en
Publication of NO981864L publication Critical patent/NO981864L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

For bedre metoder for oppløsning av biologisk aktive forbindelser, for eksempel proteiner i et hydrofobt oppløsningsmiddel.For better methods of dissolving biologically active compounds, for example, proteins in a hydrophobic solvent.

NO981864A 1995-10-25 1998-04-24 Upl ° sningsmetoder NO981864L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9521805.3A GB9521805D0 (en) 1995-10-25 1995-10-25 Solubilisation methods
PCT/GB1996/002609 WO1997015289A1 (en) 1995-10-25 1996-10-25 Solubilisation methods

Publications (2)

Publication Number Publication Date
NO981864D0 NO981864D0 (en) 1998-04-24
NO981864L true NO981864L (en) 1998-06-24

Family

ID=10782854

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981864A NO981864L (en) 1995-10-25 1998-04-24 Upl ° sningsmetoder

Country Status (12)

Country Link
EP (1) EP0857061A1 (en)
JP (1) JP2000502990A (en)
KR (1) KR19990067028A (en)
CN (1) CN1202818A (en)
AU (1) AU704292B2 (en)
BR (1) BR9611343A (en)
CA (1) CA2235487A1 (en)
GB (1) GB9521805D0 (en)
NO (1) NO981864L (en)
NZ (1) NZ320442A (en)
WO (1) WO1997015289A1 (en)
ZA (1) ZA969016B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605709D0 (en) * 1996-03-19 1996-05-22 Cortecs Ltd Method
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP5143131B2 (en) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド Two-piece internal channel flow modulator for osmotic delivery system
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CN101715340A (en) 2007-04-23 2010-05-26 精达制药公司 Suspension formulation of insulinotropic peptide and application thereof
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
KR102093612B1 (en) 2009-09-28 2020-03-26 인타르시아 세라퓨틱스 인코포레이티드 Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
RU2760007C2 (en) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Polypeptides selective to glucagon receptors and their application methods
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CA3049034A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012115A1 (en) * 1978-12-04 1980-06-11 Ciba-Geigy Ag Pharmaceutical compositions for topical treatment of virus infections
US4411882A (en) * 1978-12-21 1983-10-25 Sandoz Ltd. Galenical compositions

Also Published As

Publication number Publication date
AU7317896A (en) 1997-05-15
BR9611343A (en) 1999-12-28
CN1202818A (en) 1998-12-23
NO981864D0 (en) 1998-04-24
ZA969016B (en) 1998-04-28
CA2235487A1 (en) 1997-05-01
JP2000502990A (en) 2000-03-14
EP0857061A1 (en) 1998-08-12
WO1997015289A1 (en) 1997-05-01
KR19990067028A (en) 1999-08-16
NZ320442A (en) 1999-10-28
GB9521805D0 (en) 1996-01-03
AU704292B2 (en) 1999-04-15

Similar Documents

Publication Publication Date Title
NO981864L (en) Upl ° sningsmetoder
DE69104777D1 (en) Oral drug forms of biologically active proteins.
NO961963D0 (en) Microcapsules containing suspensions of biologically active compounds
HUP9603305A2 (en) [(pyrrolyl-carbonyl)-amino]-naphtalene derivatives, capable for improving biological availability of biologically active compounds
ES2088160T3 (en) CHEMICAL FORMULATION AND PROCESS.
ATE203025T1 (en) REVERSE TURN MIMETICS AND RELATED METHOD
DK0600866T3 (en) Preparations and Methods for Identifying Biologically Active Molecules
EA199800288A1 (en) DERIVATIVES 5-O-DEOZOMINIL-6-O-METHYLERITRONOLID A, METHOD OF THEIR PRODUCTION AND THEIR APPLICATION FOR OBTAINING BIOLOGICAL ACTIVE PRODUCTS
DK366889D0 (en) peptide
ES2148259T3 (en) PRO-PROFARMACOS, ITS PRODUCTION AND USE.
RU95108590A (en) Imidazole derivatives
NO982567D0 (en) Improved Hydrogenolysis of 2,4,6,8,10,12-Hexaazatetracyclo (5.5.0.05.903.11) dodecane
ES2176456T3 (en) PROCEDURE FOR THE PREPARATION OF AN HIV PROTEASA INHIBITING COMPOUND.
EP0695171A1 (en) LONOSPHERES CONTAINING GONADOTROPHIN
DE3863366D1 (en) ANTIBIOTIC VERMISPORIN, METHOD FOR THE PRODUCTION THEREOF AND THE SAME PHARMACEUTICAL COMPOSITION CONTAINING IT AS AN ACTIVE ANTIBACTERIAL ACTIVE SUBSTANCE.
ATE250625T1 (en) ESSENTIALLY PURE ZONULIN AS A PHYSIOLOGICAL MODULATOR OF ßTIGHT JUNCTIONSß IN MAMMALS
SE9501285L (en) Process for producing biologically active proteins
GR1001597B (en) New biologically active derivatives of furnaceamine, pharmaceutical compounds that contain them and a method for their preparation.
AU4515996A (en) Methods for increasing the bioavailability of biological active agents
DE59609043D1 (en) Solid solutions of 1,4-diketopyrrolopyrroles
NO902626L (en) PROCEDURE FOR STABILIZING BIOLOGICALLY ACTIVE COMPOUNDS IMMOBILIZED AT SOLID PHASES.
DE69616944D1 (en) USE OF DES-ASPARTATE-ANGIOTENSIN I AS AN ACTIVE SUBSTANCE AGAINST HEART HYPERTROPHY
EA199800610A1 (en) A METHOD OF CREATING PHYSIOLOGICAL ACTIVE COMPOUNDS
YU48831B (en) LHRH - ANTAGONISTS AND PROCEDURE FOR THEIR PRODUCTION
NO884721D0 (en) PROCEDURE FOR MANUFACTURING BIOLOGICALLY ACTIVE COMPONENTS.